Exicure (XCUR) Competitors $11.19 +5.37 (+92.27%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends XCUR vs. UNCY, VIRI, JATT, VTVT, TARA, DBVT, ACAB, IMMX, GANX, and CALCShould you be buying Exicure stock or one of its competitors? The main competitors of Exicure include Unicycive Therapeutics (UNCY), Virios Therapeutics (VIRI), JATT Acquisition (JATT), vTv Therapeutics (VTVT), Protara Therapeutics (TARA), DBV Technologies (DBVT), Atlantic Coastal Acquisition Corp. II (ACAB), Immix Biopharma (IMMX), Gain Therapeutics (GANX), and CalciMedica (CALC). These companies are all part of the "pharmaceutical products" industry. Exicure vs. Unicycive Therapeutics Virios Therapeutics JATT Acquisition vTv Therapeutics Protara Therapeutics DBV Technologies Atlantic Coastal Acquisition Corp. II Immix Biopharma Gain Therapeutics CalciMedica Unicycive Therapeutics (NASDAQ:UNCY) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability, community ranking and analyst recommendations. Does the MarketBeat Community prefer UNCY or XCUR? Unicycive Therapeutics received 20 more outperform votes than Exicure when rated by MarketBeat users. Likewise, 74.36% of users gave Unicycive Therapeutics an outperform vote while only 47.37% of users gave Exicure an outperform vote. CompanyUnderperformOutperformUnicycive TherapeuticsOutperform Votes2974.36% Underperform Votes1025.64% ExicureOutperform Votes947.37% Underperform Votes1052.63% Do institutionals and insiders believe in UNCY or XCUR? 40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 42.8% of Exicure shares are held by institutional investors. 24.1% of Unicycive Therapeutics shares are held by insiders. Comparatively, 3.9% of Exicure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has stronger valuation and earnings, UNCY or XCUR? Exicure has higher revenue and earnings than Unicycive Therapeutics. Exicure is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUnicycive Therapeutics$680K77.76-$30.54M-$0.97-0.53Exicure$28.83M0.84-$16.91M-$2.07-5.41 Do analysts rate UNCY or XCUR? Unicycive Therapeutics currently has a consensus price target of $5.13, suggesting a potential upside of 906.09%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Unicycive Therapeutics is more favorable than Exicure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Unicycive Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Exicure 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer UNCY or XCUR? In the previous week, Unicycive Therapeutics had 14 more articles in the media than Exicure. MarketBeat recorded 15 mentions for Unicycive Therapeutics and 1 mentions for Exicure. Unicycive Therapeutics' average media sentiment score of 0.80 beat Exicure's score of 0.42 indicating that Unicycive Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Unicycive Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exicure 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, UNCY or XCUR? Unicycive Therapeutics has a beta of 2.29, suggesting that its stock price is 129% more volatile than the S&P 500. Comparatively, Exicure has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500. Is UNCY or XCUR more profitable? Unicycive Therapeutics' return on equity of 0.00% beat Exicure's return on equity.Company Net Margins Return on Equity Return on Assets Unicycive TherapeuticsN/A N/A -29.88% Exicure N/A -190.90%-36.75% SummaryUnicycive Therapeutics beats Exicure on 15 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Exicure News Delivered to You Automatically Sign up to receive the latest news and ratings for XCUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XCUR vs. The Competition Export to ExcelMetricExicurePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.64M$6.48B$5.06B$8.89BDividend YieldN/A8.11%4.97%4.06%P/E Ratio-5.414.8389.0213.30Price / Sales0.84372.991,207.2881.01Price / CashN/A52.2739.1736.03Price / Book15.767.876.085.74Net Income-$16.91M$153.61M$119.07M$225.93M7 Day Performance251.89%-2.00%-1.84%-1.32%1 Month Performance327.10%-7.47%-3.65%0.60%1 Year Performance2,165.18%31.80%31.62%26.23% Exicure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XCURExicure1.7834 of 5 stars$11.19+92.3%N/A+1,914.4%$12.64M$28.83M-5.4150News CoverageGap UpHigh Trading VolumeUNCYUnicycive Therapeutics3.4448 of 5 stars$0.51+4.1%$5.13+906.1%-2.0%$50.34M$680,000.000.009Analyst RevisionVIRIVirios Therapeutics0.741 of 5 stars$2.60+40.5%$3.00+15.4%+254.9%$50.07MN/A-9.635Gap DownJATTJATT AcquisitionN/A$2.90-7.9%N/A-29.5%$50.03MN/A0.003High Trading VolumeVTVTvTv Therapeutics0.3329 of 5 stars$15.46-5.9%N/A+10.4%$49.46M$2.02M-3.419TARAProtara Therapeutics2.1378 of 5 stars$2.31-0.4%$24.00+939.0%+102.6%$47.86MN/A0.0030Analyst RevisionDBVTDBV Technologies3.2676 of 5 stars$0.51+4.1%$6.00+1,081.1%-70.2%$47.38M$15.73M0.00106Stock SplitGap UpACABAtlantic Coastal Acquisition Corp. IIN/A$5.77-47.1%N/A-45.6%$47.14MN/A0.004High Trading VolumeIMMXImmix Biopharma2.28 of 5 stars$1.82+7.1%$7.00+284.6%-58.7%$46.76MN/A0.009Negative NewsHigh Trading VolumeGANXGain Therapeutics2.4867 of 5 stars$1.66-3.5%$7.33+341.8%-39.0%$45.62M$50,000.000.0020News CoverageGap DownCALCCalciMedica3.0723 of 5 stars$3.45+3.0%$19.33+460.4%+10.6%$45.16MN/A0.0030 Related Companies and Tools Related Companies Unicycive Therapeutics Alternatives Virios Therapeutics Alternatives JATT Acquisition Alternatives vTv Therapeutics Alternatives Protara Therapeutics Alternatives DBV Technologies Alternatives Atlantic Coastal Acquisition Corp. II Alternatives Immix Biopharma Alternatives Gain Therapeutics Alternatives CalciMedica Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:XCUR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exicure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exicure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
